Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Oncogene. 2014 Sep 22;34(29):3770–3779. doi: 10.1038/onc.2014.304

Figure 6. Survivin antagonists inhibit proliferation of human SHH-driven MB cells.

Figure 6

Cells isolated from LDE225-sensitive xenograft DMB012 (A) and LDE-insensitive xenografts RCMB018 (B) and ICb-984MB (C) were treated for 48 hr with DMSO, LDE225, YM155 or S12, and analyzed for thymidine incorporation following a 12-16 hr pulse. All tumor cells were sensitive to YM155 inhibition and high dose S12 treatment (DMB012 p<0.01 for all doses including LDE225, RCM018 and ICb-984MB p<0.03 for YM155 and 10μg/ml S12 while LDE and 20μg/ml S12 were not significant with p>0.08). All stats were calculated by ANOVA and post hoc student's t-test. Data represent mean +/- SD and are representative of 3 experiments.